Pharma

Your Article Summary

See Latest Articles

Data Presented from Two Phase 3 ERBITUX Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
Bristol Myers-Squibb Company, 09/24/09

According to a recent retrospective analysis of the pivotal Phase 3 CRYSTAL study, ERBITUX, when added to FOLFIRI, was shown to increase median overall survival to 19.9 months in an intent–to–treat population of first–line metastatic colorectal cancer patients compared to 18.6 months in those receiving FOLFIRI alone.

Today in Conferences/Meetings...keeping you current

Receive free subspecialty "5-minute updates" via email

Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas Wednesday, December 9
Repligen, 12/09/09

Allos Therapeutics' FOLOTYN Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Treated with Stem Cell Transplant
Allos Therapeutics, 12/08/09

ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting
ARIAD Pharmaceuticals, 12/08/09

 See all of Conferences/Meetings

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Important progress in treatment of early and late stage breast cancer with Herceptin, Avastin and T-DM1
Roche, 12/10/09

Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09

Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09

 See all of Research & Development